Alphabet, GeneScience, AstraZeneca, Shire, Novartis, Ping An, KPC and Stevanato are in line for exits after the drug delivery technology developer filed to go public.

US-based biologics delivery technology developer Rani Therapeutics has filed to raise up to $100m in an initial public offering that would allow several corporate investors to exit. Rani is developing a capsule called the RaniPill, which would allow for biologics to be delivered orally to patients, instead of through subcutaneous or IV injection. The IPO…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.